Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00487136 · ClinicalTrials.gov registry record · Phase 1
Interaction Between ABT-335, Rosuvastatin and Warfarin
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00487136: Completed Phase 1 study, sponsored by AstraZeneca.
NCT00487136 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 45 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00487136, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This is a multiple-dose, double-blind, randomized, single-center, parallel-group study in adult male subjects in general good health.
Interventions
- DRUG Warfarin
- DRUG warfarin plus ABT-335 plus rosuvastatin 5 mg
- DRUG warfarin plus ABT-335 plus rosuvastatin 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2007-06 |
| Est. Completion | 2007-07 |
| Phase | Phase 1 |
What the finished NCT00487136 record still lists
NCT00487136 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 3 interventions - of which Warfarin is the first listed.
NCT00487136 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00487136 about?
NCT00487136 is a clinical study titled "Interaction Between ABT-335, Rosuvastatin and Warfarin". This is a multiple-dose, double-blind, randomized, single-center, parallel-group study in adult male subjects in general good health.
What is the current status of trial NCT00487136?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2007-06. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00487136?
The interventions under investigation include: Warfarin (DRUG), warfarin plus ABT-335 plus rosuvastatin 5 mg (DRUG), warfarin plus ABT-335 plus rosuvastatin 20 mg (DRUG).
Who is sponsoring clinical trial NCT00487136?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00487136's enrollment target sits among peer trials
45 1066th of 2000 higher than 915 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia